The anti-inflammatory therapeutics market is expected to be valued at 130.6 billion USD by 2026, reflecting the demand for effective novel therapeutics for inflammatory disorders, which constitutes significant global disease burden.

Inflammation is the body’s way of initiating the healing process following injury by initiating the recruitment of immune cells and mediator release. Inflammation represents a key biological process and, as such, occurs not only in response to infection but also to a diverse range of disease states such as cancer and diabetes. It is well-established that inflammation, whether attributable to autoimmunity (e.g. rheumatoid arthritis; RA) or chemical mediators (e.g. gout), causes nociceptive pain.

Both in vitro and in vivo models of inflammation are commonly used to characterise the inflammatory response to pro-inflammatory stimuli such as lipopolysaccharide (LPS) and adenosine triphosphate (ATP), providing a platform on which to test the efficacy of novel anti-inflammatory therapeutics.

Examples of models we offer:

  • •
    PBMCs: LPS-induced inflammation in rodent and human cells
  • •
    Whole Blood: LPS-induced inflammation in rodent and human samples
  • •
    NLRP3-mediated inflammation: LPS and ATP-induced IL-1Beta release in human whole blood
  • •
    LPS and cytokine induced systemic inflammation in rodents
  • •
    LPS and cytokine induced neuroinflammation in rodents
  • •
    Clinical sample procurement and analysis

Examples of end points:

  • •
    Analysis of cytokines and chemokines in fluids and tissue
  • •
    Immunohistochemistry
  • •
    Measure activation of intracellular signalling pathways by infrared western blotting
  • •
    In vivo physiological measurements  (e.g., body temperature)